Milestone Pharmaceuticals Inc

NASDAQ:MIST   3:59:44 PM EDT
6.68
0.00 (0.00%)
Products, Regulatory

Milestone Pharmaceuticals Announces First Patient Enrolled In Rapid, A Pivotal Phase 3 Study Of Etripamil In Psvt

Published: 11/18/2020 12:22 GMT
Milestone Pharmaceuticals Inc. (MIST) - Milestone Pharmaceuticals Announces First Patient Enrolled in Rapid, a Pivotal Phase 3 Study of Etripamil in Psvt.
Milestone Pharmaceuticals Inc - Rapid Results Expected Late 2021/early 2022.
Milestone Pharmaceuticals Inc - Rapid Investigates Efficacy of Second Dose of Etripamil for Patients With Persistent Psvt.